MERIDIAN: 52-week results from a phase 2, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of pegcetacoplan in people with ALS (NEALS 2023 ALS) - Apellis Medical Hub

MERIDIAN: 52-week results from a phase 2, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of pegcetacoplan in people with ALS

Share Via Email

Back to Conference Resources

ALS Congress Presentations Northeast Amyotrophic Lateral Sclerosis Consortium (NEALS) 2023

The following information is available for educational purposes only. The information is not to be re-purposed or re-used in its current form or presentation for any personal or professional use. Apellis reserves the right to withdraw, modify or change the information that is available on this website at any time.